1.Empirical Study on the Interaction between Foreign Economic Trade and Pharmaceutical Manufacturing Industry Based on the Annual Data of 1998-2018 in China
China Pharmacy 2020;31(14):1670-1676
OBJECTIVE: To invest igate the intraction between China ’s foreign economic trade and pharmaceutical manufacturing industry ,in order to provide the reference for China ’s foreign economic trade growth and pharmaceutical manufacturing industry development in the future. METHODS :By collecting the data of China ’s foreign economic trade and pharmaceutical manufacturing industry during 1998-2018 issued by National Bureau of Statistics ,China Statistics Yearbook on High Technology Industry and China Statistics Yearbook on Scientific Technology ,referring to relevant literature method ,index system was established that includes the foreign economic trade system and the pharmaceutical manufacturing system. CRITIC method was adopted to assign the weight of data index and calculate comprehensive evaluation data. VAR model was used to analyze the interaction between China ’s foreign economic trade and pharmaceutical manufacturing industry and put forward the suggestions. RESULTS & CONCLUSIONS :From the results of cointegration test ,foreign economic trade development played a strong role in promoting and driving pharmaceutical manufacturing industry development (correlation coefficient was 0.432 198);from the results of Granger causality test ,the development of foreign economic trade was the Granger cause for pharmaceutical manufacturing industry development (confidence probability was lower than 0.001),but the pharmaceutical manufacturing industry development was not the Granger ’s reason for foreign economic trade (confidence probability was 0.358). By the results of impulse response and variance decomposition ,it reflected an interrelationship between the two ,but the contribution of foreign economic trade to the development of pharmaceutical manufacturing is relatively small. It is suggested that China ’s pharmaceutical manufacturing enterprises should grasp the market demand and trade opportunities in time ,and further expand the scale of business by providing high quality pharmaceutices products ;make full use of new trade mode and speed up the circulation of pharmaceutical products in economic and trade activities so as to further expand the domestic and foreign markets of pharmaceutical products ;the state should formulate and improve the preferential and supporting policies for pharmaceutical manufacturing industry as soon as possible to reduce the burden for pharmaceutical manufacturing enterprises. In addition ,from the national level and the enterprise level ,we should appropriately increase the investment in scientific research of pharmaceutical manufacturing industry and increase industry cultiration,so as to promote the rapid development of pharmaceutical manufacturing industry and realize a virtuous circle of mutual promotion of foreign economic trade and pharmaceutical manufacturing industry.
2.Preliminary application experience of disk microfluidic chip for detecting CALR gene mutation in patients with cerebral infarction
Guojun CAO ; Yunchun LI ; Xiao XU ; Zhifang XING ; Yutao SHEN ; Qingyun ZHANG ; Yueru TIAN ; Xueen FANG ; Ming GUAN
Chinese Journal of Laboratory Medicine 2022;45(1):45-50
Objective:To establish a disk (CD) microfluidic chip detection platform for the rapid detection of CALR-1 and CALR-2 mutations in patients with cerebral infarction, and summarize its clinical application value.Methods:Based on microfluidic technology and loop mediated isothermal amplification technology, a CD microfluidic chip detection platform for simultaneous detection of CALR-1 and CALR-2 gene mutations were established, and the sensitivity, specificity, repeatability and accuracy of the platform were verified. A total of 124 patients with cerebral infarction treated in Huashan Hospital, Shanghai Medical College, Fudan University from November 2019 to March 2021 were prospectively selected into the experimental group; and 80 healthy subjects were included in the control group. The CALR-1 and CALR-2 gene mutations in anticoagulant peripheral blood samples were detected by the CD microfluidic chip. Each chip could detect 4 samples at the same time and synchronously detect 3 indexes of each sample. The detection results could be obtained after isothermal amplification for 40 min. At the same time, sequencing method was used to verify the test results, and the consistency of the results of the two detection methods was compared.Results:Using this CD microfluidic chip platform, the synchronous amplification of 3 indexes in the sample could be completed within 40 min without the need of thermal circulation, and the whole detection process of the sample could be completed within 60 min. For samples with a high concentration of target nucleic acid, typical positive signals could be visualized after amplification for 10 min, and the test results would be available within 30 minutes after receiving the samples. The detection sensitivity of CD microfluidic chip method for CALR-1 and CALR-2 mutation load concentration was 1.0% and 0.5% respectively. Nonspecific amplification was not observed for the non-target nucleic acid samples, indicating the high specificity of this method. The coincidence rates of intra and inter batch repeatability were 100% (20/20) respectively. Two samples with CALR gene mutation were found in the cerebral infarction group, both of which were CALR-1 mutations (L367fs*46). There was no CALR-1 or CALR-2 mutation in the control group. The detection results of CD microfluidic chip method were completely consistent with the sequencing verification results (100% [204/204]).Conclusions:The CD microfluidic chip method could be used for the detection of CALR-1 and CALR-2 gene mutations in clinical samples of patients with cerebral infarction. This method has the advantages of high detection sensitivity, good detection specificity, fast detection speed and high detection flux, which is helpful to clarify the etiology of patients with cerebral infarction.
3.Study on the Construction of Reverse Supply Chain for Expired Drugs under Block Chain Perspective
China Pharmacy 2019;30(24):3342-3349
OBJECTIVE: To provide reference for reducing the harm of expired drugs to public health, improving the technical level of drug recovery, and realizing the green recycling economy of drugs. METHODS: The literatures analysis and field investigation is conducted to analyze the development status and the main problems in the construction of the reverse supply chain of expired drugs. According to the technical characteristics of block chain, the feasibility of building the reverse supply chain of expired drugs is analyzed. In order to verify the feasibility of the application of block chain technology in the construction of the expired drug reverse supply chain, this paper attempts to build the expired drug reverse supply chain from the perspective of block chain, and uses the system dynamics method to build a simulation model for each participant in the drug reverse supply chain and its operationing efficiency. RESULTS & CONCLUSIONS: The reverse supply chain of expired drugs constructed by the block chain technology could effectively solve the main problems of the reverse supply chain of expired drugs in China, such as many levels of participants, high logistics cost, low level of information. The simulation results showed when using block chain technology, the recovery efficiency and recovery quantity of each participant in the supply chain were significantly increased. The recovery efficiency of consumers and retailers increased from 20% to 83%, and those of distributors and manufacturers increased from 40% and 50% to 83%, respectively. The recovery quantity of each participant also increased significantly with the increase of recovery efficiency. In the actual construction of the reverse supply chain of expired drugs, the enterprises involved in the drug supply chain should be taken as the leading role, and the multi-party participation of government agencies, industry platforms and consumers should be emphasized. Drug supply chain participating enterprises should use block chain technology to strengthen information communication between enterprises, establish an efficient information platform, and promote and guide consumers to actively participate in the construction of the reverse supply chain of expired drugs. The government should give full play to the guiding role of policy and strengthen the policy guarantee; the industry platform should learn from international advanced cases to form industry standards for the recovery process of expired drugs; consumers should fully understand the hazards of expired drugs and actively participate in the recovery of expired drugs.